Search research articles
Contact Us
Filters
Showing results (61-70 of 84) with videos related to
Page
of 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 9, 2021
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Catherine C Smith, Aaron D Viny, Evan Massi, et al.
Cancer Research
|
December 30, 2011
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation
Fei Su, William D Bradley, Qiongqing Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2012
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
Muling Mao, Feng Tian, John M Mariadason, et al.
Nature Medicine
|
December 19, 2018
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
Zhan Yao, Yijun Gao, Wenjing Su, et al.
Science Signaling
|
August 20, 2015
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Rachel Ramsdale, Robert N Jorissen, Frederic Z Li, et al.
Nature Communications
|
August 23, 2019
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model
Elizabeth Spangenberg, Paul L Severson, Lindsay A Hohsfield, et al.
JCI Insight
|
May 22, 2024
BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia
Audrey L Smith, Sydney A Skupa, Alexandria P Eiken, et al.
Cancer Research
|
October 7, 2004
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
Scott M Wilhelm, Christopher Carter, Liya Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2009
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2
D Gareth Evans, Michel Kalamarides, Kim Hunter-Schaedle, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 16, 2013
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
Chao Zhang, Prabha N Ibrahim, Jiazhong Zhang, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 84) with videos related to
Sort By:
Page
of 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 9, 2021
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Catherine C Smith, Aaron D Viny, Evan Massi, et al.
Cancer Research
|
December 30, 2011
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation
Fei Su, William D Bradley, Qiongqing Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2012
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
Muling Mao, Feng Tian, John M Mariadason, et al.
Nature Medicine
|
December 19, 2018
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
Zhan Yao, Yijun Gao, Wenjing Su, et al.
Science Signaling
|
August 20, 2015
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Rachel Ramsdale, Robert N Jorissen, Frederic Z Li, et al.
Nature Communications
|
August 23, 2019
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model
Elizabeth Spangenberg, Paul L Severson, Lindsay A Hohsfield, et al.
JCI Insight
|
May 22, 2024
BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia
Audrey L Smith, Sydney A Skupa, Alexandria P Eiken, et al.
Cancer Research
|
October 7, 2004
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
Scott M Wilhelm, Christopher Carter, Liya Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2009
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2
D Gareth Evans, Michel Kalamarides, Kim Hunter-Schaedle, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 16, 2013
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
Chao Zhang, Prabha N Ibrahim, Jiazhong Zhang, et al.
Page
of 9